AU2767292A - Cyclic peroxyacetal compounds - Google Patents

Cyclic peroxyacetal compounds

Info

Publication number
AU2767292A
AU2767292A AU27672/92A AU2767292A AU2767292A AU 2767292 A AU2767292 A AU 2767292A AU 27672/92 A AU27672/92 A AU 27672/92A AU 2767292 A AU2767292 A AU 2767292A AU 2767292 A AU2767292 A AU 2767292A
Authority
AU
Australia
Prior art keywords
formula
compound
oxygenation
compounds
followed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU27672/92A
Other versions
AU659505B2 (en
Inventor
Richard Kingston Haynes
Simone Charlotte Vonwiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYDNEY THE, University of
Original Assignee
Sydney The, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sydney The, University of filed Critical Sydney The, University of
Priority to AU27672/92A priority Critical patent/AU659505B2/en
Publication of AU2767292A publication Critical patent/AU2767292A/en
Application granted granted Critical
Publication of AU659505B2 publication Critical patent/AU659505B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05—Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/38—Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/225—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/553—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/46—Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymerization Catalysts (AREA)

Description

CYCLIC PEROXYACETAL COMPOUNDS
Technical Field
This invention relates to novel cyclic peroxyacetal compounds and in particular relates to compounds related to qinghaosu (Artemisinin) which is a naturally occurring biologically active compound.
Background of the Invention
The present invention provides novel compounds which are structurally similar to the naturally occurring biologically active compound qinghaosu (Artemisinin) which has the following formula:
Qinghaosu is a potent anti-malarial which has been successfully used to treat patients suffering from malaria. The re-emergence of strains of malaria resistant to conventional (chloroquine) therapy is posing a world-wide problem and indeed, there is no universally acceptable cure at the present time. Qinghaosu occurs to the extent of about 0.1% (dry weight) in an annual shrub, qinghao or Artemisia a nnua, which grows in most provinces of China. Unfortunately, the world demand for qinghaosu far exceeds the supply, and there is considerable pressure to develop bioactive analogues and derivatives or to develop alternative sources for the compound.
Some of the novel compounds have activities superior to that of qinghaosu and furthermore these compounds will be suitable for preparing conjugate drugs for the treatment of malaria and other parasitic and viral diseases.
The novel compounds can also be used as building blocks because of their reactive side chain and other active drugs can be linked via these side chains to form conjugate drugs.
Disclosure of the Invention
In one aspect, the present invention provides compounds of general formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof
wherein
l = 1, 2 or 3
n is an integer from 1-6
where X is independently selected from
H, =O,=CH2, aryl, COR, OR, COOR or
X = -(CR1R2)r-R3 where r is an integer from 1-10 and where r > 1, optionally at least 1 carbon atom can be replaced by O, S or N;
R1, R2 and R3 are independently selected from
H; alkyl, alkenyl, alkynyl, aryl, each optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, aryl, halogen, OR, CF3, NO2, COOR, NRR',
SR, COR, CONRR', SO3R, SO2NRR', SR, SOR, and SO2R, where R and R' are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted arylalkyl wherein the optional substituents are as defined above.
Preferred compounds of formula (I) have the following structural formulae:
In another aspect the present invention provides a process for preparing compounds of formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof comprising: (A) carrying out at least one addition reaction on a compound of formula (II) having a -C=O functionality
to provide another compound of formula (II) with an alcoholic functionality at the (C)1-(V)r group and then followed by oxygenation to give a compound of formula (I);
where V is as defined for X; r and l are as defined above; (B) directly oxygenating a compound of formula (II) where there is a carboxylic functionality at the
(C)l-(V)r reactive chain and also a further functional group to facilitate subsequent addition reaction, to provide compounds of formula (I) and then carrying out a suitable addition reaction to provide the required side chain; or
(C) for compounds of formula (I) where l=1; carrying out one or more of the following steps on a compound of general formula (II): (i) oxidative degradation and
(ii) reduction followed by oxygenation to give compounds of formula (I). Best Mode of Carrying out the Invention
The oxygenation step is basically, the process described in PCT/AU90/00456 (WO 91/04970) and that disclosure is incorporated herein by reference. The oxygenation is preferably carried out as a "one-pot" reaction and involves oxygenation of a compound of formula (II) to provide a hydroperoxide derivative and without isolation further oxygenation in the presence of one or more oxygenating metal catalysts to give a compound of formula (I). The oxygenation of the hydroperoxy compound in the presence of one or more catalysts provides an oxygenation-cleavage-cyclization reaction to give the cyclic peroxyacetal compounds of formula (I).
The oxygenation-cleavage-cyclization reaction is typically carried out by treating with one or more transition metal catalysts such as Cu(OSO2CF3)2, Cu(II) propionate, copper (II) 2-ethylhexanoate, other copper (II) carboxylic salts, and various iron (III) salts such as
Fe(phenanthroline)3(PF6)3. Other catalysts that may be used are cobalt (II) and cobalt (III) salts. Preferably this reaction is carried out in a solvent such as a mixture of acetonitrile and dichloromethane and by treating with one of the above mentioned catalysts, or with a combination of the copper and iron catalysts. Other suitable solvents include hexane, ethyl acetate and the like.
Preferred solvents for the Grignard addition reactions are diethyl ether, or THF but any other solvent such as benzene or other ether solvent would be suitable.
The reaction is typically initially carried out at the temperature of 0°-5°C and continued at room temperature.
Other addition reactions are typically carried out in
CHCI3 and CH2Cl2 with an amine base. MeOH and aqueous
MeOH may also be used and bases such as Na2CO3, K2CO3 or
NaHCO3 can also be used. The reactions are preferably carried out at room temperature.
Oxidative degradation is preferably carried out using cupric acetate, 2,2'-bipyridyl and DABCO in DMF under atmospheric oxygen at between about 70°-75°C for about 12 hours. The reduction is preferably carried out in methanol or other alcoholic solvent with NaBH4 at about 0°C. Other reducing agents with appropriate solvents may also be used*
Preferably the starting compound for process A is the aldehyde 2 having the following structure
This is preferably treated with Grignard reagents or other organometallic reagents such as those derived from lithium, copper or zinc to provide compounds of the following formulae: which are then oxygenated to provide the corresponding compounds of formula (I):
The aldehyde is preferably prepared from qinghao acid which has the following formula:
Qinghao acid occurs to the extent of 1-3% (dry weight) in Artemisia an nua, which is much greater than the natural occurrence of qinghaosu and is easily extracted from the plant.
The starting material for the process B is preferably qinghao acid which is oxygenated to provide dehydro- qinghaosu of the following formula
on which is carried out various addition reactions to provide compounds of formula (I). The starting material for process C is also preferably the aldehyde having the structural formula 2. This aldehyde is typically prepared from qinghao acid by carrying out the following steps.
1. methylation to provide the unsaturated methyl ester;
2. reduction to provide the saturated methyl ester;
3. reduction to provide the alcohol;
4. oxidation to provide the aldehyde.
The skilled addressee would understand that the process of the invention may result in one or more stereogenic (chiral) centres being formed resulting in stereoisomers. Thus it is to be understood that the present invention includes within its scope the preparation of stereoisomers and also encompasses any isomers per se or mixture thereof.
Most of the starting compounds of formula (II) are also novel and form part of the present invention. Accordingly, in yet another aspect, the present invention provides compounds of general formula (II)
wherein V is as defined for and are as hereinbefore defined; provided that the (C)l-(V)r group is not CH(CH3)CH2OH and CH(CH3)C(=O)H. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof in a pharmaceutically acceptable carrier and/or diluent. Pharmaceutical compositions containing a compound of formula (I) as the active ingredient in admixture with a pharmaceutically acceptable carrier or diluent can be prepared according to conventional pharmaceutical formulating techniques. The carrier may be of any form depending on the form of preparation desired for administration, eg intravenous, oral or parenteral.
In yet another aspect, the present invention provides a method of treatment or prophylaxis of parasitic or viral diseases in a mammal comprising administering to the mammal a compound of formula (I), a pharmaceutically acceptable salt thereof or a stereoisomeric form thereof.
Specific embodiments of the present invention are illustrated by the following preparative examples. It will be understood, however, that the invention is not confined to the specific limitations set forth in the individual examples. PREPARATION OF STARTING COMPOUNDS
Preparation of Derivatives of Qinghao Acid
Example 1
a) Dihydroqinghao alcohol (1) and dihydroqinghao aldehyde (2)
Qinghao acid (307 mg; 1.31 mmol) was firstly converted into its methyl ester by heating it with dimethyl sulfate (198 mg; 1.57 mmol; 0.15 ml) and potassium carbonate (199 mg; 1.44 mmol) in acetone (15 ml) under gentle reflux for 2 h. The crude product was then dissolved in methanol (7 ml) and treated with sodium borohydride (72 mg; 1.90 mmol) in the presence of nickel boride, which was preformed from NiCl2.6H2O (30 mg; 0.13 mmol), at -30° to give the saturated ester after acidic workup. This was then dissolved in diethyl ether (7 ml) and treated with lithium aluminium hydride (1 M solution in THF), with cooling in ice, until complete conversion to the saturated alcohol was observed by t.l.c. The reaction mixture was heated under gentle reflux for 40 min. before being cooled and quenched with ethyl acetate (5 ml) and water (2 ml). Sodium sulfate was added to the stirred mixture until the excess water had been absorbed and it was then removed by filtration, and washed with more ether. The filtrate was evaporated to dryness to give dihydroqinghao alcohol (1). The pure alcohol could be isolated by flash chromatography (ether/light petroleum, 40:60) in greater than 90% yield, 1H NMR spectrum (200 MHz, CDCl3) δ 0.864 (3H, d, J4-Me,4 = 6.4 Hz, 4-CH3), 0.997 (3H, d, J3,,2, = 6.8 Hz, H3'), 1.630 (3H, m, 7-CH3), 2.475 (1H, br s, Wh/2 = 11.5 Hz, OH), 3.522 (1H, dd, Jgem=10.6, J1 ,,2, = 6.2 Hz, H1'), 3.740 (1H, dd, Jgem = 10.6, J1,,2, =3.3 Hz, E1'), 5.218 (1H, m, H8). However, in general, the residue after evaporation of the filtrate, without purification, was immediately submitted to Swern oxidation conditions. Thus, DMSO (0.37 ml; 5.2 mmol) in dichloromethane (2 ml) was added dropwise to a solution of oxalyl chloride (0.23 ml; 2.6 mmol) in dichloromethane (8 ml) at between -50° and -60°. After 5 min. the crude alcohol (288 mg) in dichloromethane (4 ml) was added dropwise at the same temperature and after 15 min. triethylamine (1.09 ml; 7.8 mmol) was added. Stirring was continued at -60° for 5 min. and then the whole was allowed to warm to room temperature over 20 min. Aqueous workup afforded the aldehyde (2) which was submitted to flash chromatography (ether/light petroleum, 5:95) to give a colourless oil [228 mg; 79% from qinghao acid]. The aldehyde was found to be a 6.2:1 mixture of diastereomers and as such was used to prepare the other qinghao acid derivatives. 1H NMR spectrum (200 MHz, CDCl3) δ 0.877 (3H, d, J4-Me,4 = 6.3 Hz, 4-CH3), 1.067 (3H, d, J3,2, = 7.0 Hz, H3'), 1.638 (3H, m, 7-CH3), 5.132 (1H, m, H8), 9.588 (1H, d, J1,2, = 4.2 Hz, H1').
Example 2
b) Ethyl alcohol (3)
The aldehyde (50.6 mg; 0.23 mmol) was dissolved in diethyl ether (3 ml) and treated with ethyl magnesium bromide in ether with cooling in an ice bath. The whole was then stirred at room temperature for 30 min. before being quenched with aqueous ammonium chloride solution
(ice bath). Acidic workup gave the crude alcohol which was purified by flash chromatography (ether/light petroleum, 20:80) as a colourless viscous oil (48.8 mg; 85%) and as a 85:15 mixture of epimers. vmax 3611 m, 3466 br m (OH), 3011 m, 2964 s, 2924 vs, 2872 s, 1456 m, 1380 m, 1236 w, 982 m, 951 m, cm'1. 1H NMR spectrum (200 MHz, CDCl3) d 0.846 (3H, d, J1,,2, = 6.5 Hz, H1'), 0.868 (3H, d, J4-Me,4 = 6.3 Hz, 4-CH3), 0.955 (3H, t, J5,,4, = 7.4 Hz, H5'), 1.632 (3H, m, 7-CH3), 2.479 (1H, br s, Wh/2 = 11.3 Hz, OH), 3.736 (1H, m, H3'), 5.188 (1H, m, H8). Mass spectrum: m/z 250 (M, 2%), 232 (M-H20, 22), 189 (37), 162 (100), 81 (41). Example 3
c) Phenyl alcohol (4)
The aldehyde (48 mg; 0.22 mmol) in ether (4 ml) was treated with phenyl magnesium bromide in ether as described above. Flash chromatography (ether/light petroleum, 20:80) of the crude product gave the phenyl alcohol (4) as a colourless viscous oil (55.8 mg; 86%). This was found to be a 76:24 mixture of epimers with respect to the hydroxyl group. Partial 1H NMR spectrum (200 MHz, CDCI3, *denotes minor epimer) δ *2.340 (1H, br s, Wh/2 = 11.3 Hz, OH), 2.512 (1H, br S, Wh/2=11.3 Hz, OH), *5.043 (1H, d, J1,,2, = 4.3 Hz, H1'), 5.107 (1H, m, H1'), 5.171 (1H, m, H8), *5.277 (1H, m, H8).
Example 4
d) Allyl alcohol (5)
The aldehyde (95.1 mg; 0.43 mmol) in ether (5 ml) was treated with allylmagnesium bromide in ether as described above. Flash chromatography (ether/light petroleum, 20:80) of the crude product gave the allyl alcohol (5) as a colourless viscous oil (99.7 mg; 88%) and as an approximately 55:45 mixture of epimers. 1H NMR spectrum (200 MHz, CDCl3, *denotes minor epimer) δ 0.865 (3H, d, J4-Me,4 = J1,,2, = 6-2 Hz, 4"CH3, H1'), *0.881 (3H, d, J4-Me,4 = 6.5 Hz, 4-CH3), *0.897 (3H, d, J1,2, = 6.7 Hz, H1'), 1.62 (3H, m, 7-CH3, *7-CH3), 2.48 (1H, br s, Wh/2 = 12 Hz, OH, *OH), 3.83-3.95 (1H, m, H3', *H3'), 5.07-5.29 (3H, m, 2 × H6', 2 × *H6', H8, *H8), 5.73-5.97 (1H, m, H5', *H5').
Example 5
e) Hydroxy acetals (6a) and (6b)
The aldehyde (210.7 mg; 0.96 mmol) in ether (8 ml) was treated with the Grignard reagent (1.5 equiv.), derived from 5-bromopentanaldehyde diethyl acetal and magnesium in THF, with cooling in an ice bath. The whole was stirred at room temperature for 30 min. before being quenched with aqueous ammonium chloride. The product was extracted into ether, and the ether extracts were washed with brine and dried (Na2SO4). Evaporation of the solvents under reduced pressure left a pale liquid which upon purification by flash chromatography (ether/light petroleum, 35:65) gave the hydroxy diethyl acetal as a colourless viscous oil (309 mg; 85%) and as a ca. 88:12 mixture of the (2'R,3'R)- and (2'R,3'S)-diastereomers,
(6a) and (6b) respectively. These were separated by h.p.l.c. (ethyl acetate/light petroleum, 13:87, Whatman Partisil 10, preparative) to give the (2'R,3'S)-isomer
(6a) as the first to be eluted:- [α]D 20 +2.1° (c, 0.43,
CHCl3). vmaχ (CHCI3) 3536 w, 3600-3100 br s (OH), 2977 S, 2931 s, 2870 s, 1454 m, 1377 m, 1236 w, 1126 S, 1057 s, 993 m cm-1. 1H NMR spectrum (200 MHz, CHCl3) δ 0.845 (3H, d, J1,,2, = 6.4 Hz, H1'), 0.866 (3H, d, J4-Me,4 = 6.3 Hz, 4- CH3), 1.205 (6H, t, J = 7.1 Hz, CH3CH2O), 1.631 (3H, m, 7- CH3), 2.471 (1H, br s, Wh/2 = 11.5 Hz, OH), 3.41-3.72 (4H, m, CH3CH2O), 3.82 (1H, m, H3'), 4.491 (1H, t, J8,,7, = 5.6 Hz, H8'), 5.180 (1H, m, H8). Mass spectrum: m/z 379 (M-1, 0.5%), 335 (10), 317 (11), 289 (16), 189 (47), 162 (100), 143 (43), 103 (66), 85 (52), 81 (61), 69 (53), 55 (66), 47 (57), 31 (62).
The next to be eluted was the (2'R,3'S)-isomer (6b):- [α]D 20 -7.3° (c, 0.30, CHCl3) . vmax (CHCl3) 3535 w, 3600 -
3100 br s (OH), 2977 S, 2934 s, 2873 s, 1455 m, 1377 m,
1234 w, 1126 s, 1057 s, 1002 m cm-1. 1H NMR spectrum (200
MHz, CHCl3) δ 0.862 (6H, d, J1,,2 = J4-Me,4 = 6.6 Hz, H1',
4-CH3), 1.207 (6H, t, J = 7.1 Hz, CH3CH2O), 1.625 (3H, m, 7-CH3), 2.461 (1H, br s, Wfa/2 = 11.2 Hz, OH), 3.42-3.73
(4H, m, CH3CH2O), 3-82 (1H, m, H3'), 4.492 (1H, t, J8,,7, =
5.6 Hz, H81), 5.244 (1H, m, H8). Mass spectrum: m/z 379
(M-1, <0.1%), 335 (1), 317 (2), 189 (17), 162 (100), 143
(15), 103 (52), 98 (27), 95 (19), 85 (23), 81 (37), 75 (21), 69 (21), 55 (32), 43 (25), 31 (37).
Example 6
f) Hydroxy acid (7a) and (7b)
The (2'R,3'R)-hydroxy acetal (6a) (40.4 mg; 0.11 mmol) was dissolved in THF (2 ml) and treated with aqueous HCl (1 M, 1 ml) with rapid stirring at room temperature. After 30 min. the whole was extracted with ether and the combined extracts were washed with brine and dried (Na2SO4). Evaporation of the solvents left the crude aldehyde which was then dissolved in ethanol (1 ml). This was added to a stirred solution of silver nitrate ( 54 mg; 0.32 mmol) in water (0.12 ml). The resulting mixture was cooled in an ice bath, treated with aqueous KOH solution (34%, 0.105 ml), and then stirred at room temperature for 2 h. The black silver precipitate was filtered off, washing with water, and the filtrate was acidified with 3 M HCl with cooling in ice. The acidic solution was extracted with ether and the combined extracts were dried (MgSO4) and evaporated to dryness. Purification of the residue by chromatography on silicic acid (ether/light petroleum, 1:1) afforded the (2'R,3'R)-hydroxy acid (7a) as a colourless viscous oil (31.2 mg; 91% overall). 1H NMR spectrum (200 MHz, CDCI3) δ 0.864
(3H, d, J4-Me,4 = 6.3 Hz' 4-CH3), 0.881 (3H, d, J1',2' = 6-3 Hz, H1'), 1.648 (3H, m, 7-CH3), 2.390 (2H, t, J7,,6, = 7.3
Hz, H7'), 2.480 (1H, br s, Wh/2 = 12.8 Hz, OH), 3.86 (1H, m, H3'), 5.185 (1H, m, H8), 5.969 (1H, br s, Wh/2=88.5 Hz,
COOH). Similarly, the (2'R,3'S)-hydroxy acetal (6b)
(30.4 mg; 80 μmol) was converted into the (2'R,3'S)-hydroxy acid (7b) (24 mg; 93%). 1H NMR spectrum (200 MHz,
CDCI3) δ 0.866 (3H, d, J1,,2, = J4-Me,4=6-8 Hz' H1'' 4-CH3), 1.630 (3H, m, 7-CH3), 2.382 (2H, t, J7,,6, = 7.3 Hz, H7'), 2.461 (1H, br s, Wh/2 = 11.9 Hz, OH), 3.85 (1H, m, H3'), 4.435 (1H, br s, Wh/2 - 113 Hz, COOH), 5.238 (1H, m, H8). Example 7
g) Dimethyl alcohol (8)
Methylmagnesium iodide was prepared by treating magnesium turnings (80 mg; 3.3 mmol) in dry. ether (4 ml) with methyl iodide (0.17 ml; 2.8 mmol) under gentle reflux. A solution of the methyl ester of dihydroqinghao acid (138.3 mg; 0.55 mmol) in ether (3 ml) was then added dropwise at room temperature. The reaction mixture was heated under gentle reflux for a further 2 h before being cooled in ice. Aqueous ammonium chloride solution was added and the whole was extracted with ether. The combined ether extracts were washed with brine, dried ( Na2SO4) and evaporated to dryness to give the crude alcohol. This was purified by flash chromatography (ether/light petroleum, 15:85) to give the dimethyl alcohol as a crystalline solid (113 mg; 82%), m.p. 52- 54°. 1H NMR spectrum (200 MHz, CDCI3) δ 0.855 (3H, d, J4- Me,4 = 6.4 Hz, 4-CH3), 0.926 (3H, d, J1,,2, = 6.9 Hz, H1'), 1.190 (3H, s, H4' or 3-CH3), 1.249 (3H, s, H4' or 3-CH3), 0.87 - 2.0 (13H, m), 1.628 (3H, br m, Wh/2 = 5.5 Hz, 7- CH3), 2.526 (1H, br s, Wh/2 = 11.6 Hz, OH), 5.280 (1H, br m, Wh/2 = 6.8 Hz, H8). Mass spectrum: m/z 232 (M - H2O, 9%), 217 (7), 189 (25), 163 (36), 162 (100), 147 (17), 121 (13), 107 (17), 95 (14), 81 (27), 59 (40), 41 (20).
PREPARATION OF FINAL COMPOUNDS
Preparation of Deoxoqinghaosu Derivatives
Example 8
a) Deoxoqinghaosu (9)
Dihydroqinghao alcohol (1) (43.9 mg; 0.20 mmol) was mixed with acetonitrile (2.5 ml) and irradiated under oxygen at -30° for 3 h in the presence of Rose Bengal sensitiser. The resulting hydroperoxide solution was then diluted with dichloromethane (5 ml) and treated with Cu(OTf)2 (0.020 mmol, 0.1 M in acetonitrile) at -20°. The reaction mixture was stirred at -15° for a further 40 min. and was then allowed to warm to room temperature over 20 min. before being cooled to -10°. Water was added and then the whole was extracted with ether. The combined extracts were washed with brine, dried (MgSO4) and evaporated to dryness. The residue was purified by flash chromatography (ether/light petroleum, 40:60) to give deoxoqinghaosu (9) as a crystalline solid (19 mg;
36%). 1H NMR spectrum (200 MHz, CDCI3) δ 0.780 (3H, d,
J9-Me,9=7.2 Hz' 9-CH3), 0.963 (3H, d, J6-Me,6=5.9 Hz, 6-CH3), 1.43 (3H, s, 3-CH3), 3.449 (1H, dd, Jgem=11.7, J10,9=11.7
Hz, H10), 3.731 (1H, br dd, Jgem=11.7, J10,9=4 Hz, H10), 5.200 (1H, S, H12).
Example 9
b) Ethyl Deoxoqinghaosu (10)
The ethyl alcohol (3) (77.9 mg; 0.31 mmol) was dissolved in dichloromethane (1 ml) and acetonitrile (2 ml) and irradiated under oxygen at -30° for 4 h in the presence of Rose Bengal sensitiser. The resulting solution of hydroperoxides was then diluted with dichloromethane (7 ml) and treated with Cu(OTf)2 (0.031 mmol, 0.1 M in acetonitrile) at -20°. The mixture was kept at -20° for a further 40 min. and then allowed to warm to room temperature over 20 min. before being cooled to -10°. Water was added and then the whole was extracted into ether. The combined extracts were washed with brine, dried (MgSO4) and evaporated to dryness. The residue was fractionated by flash chromatography (ether/light petroleum, 10:90) to give ethyl deoxoqinghaosu (10) as a waxy solid (31.1 mg; 34%) and essentially only as the ß- epimer with respect to the ethyl group, % NMR spectrum (400 MHz, CDCl3) δ 0.860 (3H, d, JMe,9=7.6 Hz, 9-CH3), 0.958 (3H, d, JMe,6=6.0 Hz, 6-CH3), 1-034 (3H, t, J2.,1,=7.3 Hz, H2'), 1.426 (3H, s, 3-CH3), 2.687 (1H, ddq, J9,Me=7.5, J9,8a=7.5, J9,10=6.1 Hz, H9), 4-036 (1H, ddd, J10,1,=10.6, J10,9=6.0, J10,1,=2.8 Hz, H10), 5.28 (1H, s, H12). 13C NMR spectrum (50 MHz, CDCI3) δ 12.105 (C2'), 13.01 (9-CH3), 20.20 (6-CH3), 22.27 (C8), 24.87 (C1' or C5), 24.87 (C1' or C5), 26.13 (3-CH3), 30.25 (C9), 34.48 (C7), 36.57
(C4), 37.42 (C6), 44.45 (C8a), 52.03 (C5a), 77.64 (C10),
81.14 (C12a), 88.88 (C12), 103.14 (C3). Mass spectrum: m/z 296 (M+, 0.7%), 278 (M-H2O, 1), 264 (M-O2, 24), 206 (100), 193 (33), 182 (45), 165 (35), 124 (72), 95 (35), 81 (34), 69 (58), 55 (92), 43 (90), 41 (63), 29 (38).
Example 10
c) Phenyl Deoxoqinghaosu (11)
The phenyl alcohol (4) (55.4 mg; 0.19 mmol) was dissolved in dichloromethane (0.5 ml) and acetonitrile (1.5 ml) and photooxygenated at -30° for 3 h. Dilution of the reaction mixture with dichloromethane and treatment with Cu(OTf)2 as described above followed by purification of the crude product by flash chromatography (ether/light petroleum, 7:93) afforded phenyl deoxoqinghaosu (11) as a viscous oil (17.4 mg; 27%) and exclusively as the ß-epimer with respect to the phenyl group, % NMR spectrum (200 MHz, CDCI3) δ 0.508 (3H, d, JMe,9=7-7 Hz, 9-CH3), 0.987 (3H, d, JMe,6=5.6 Hz, 6-CH3), 1.383 (3H, s, 3- CH3) ,2.749 (1H, ddq, J9,Me=7.1, Jg,8a=7.1, J9,10=6.7 Hz, H9) , 5.577 (1H, S, H12), 5.723 (1H, d, J10,9=6.7 Hz, H10, 7.15- 7.34 (5H, m, C6H5) . 13C NMR spectrum (50 MHz, CDCl3) d 13.75 (9-CH3), 19.98 (6-CH3) , 24.84 (C5 or C8), 25.01 (C5 or C8) , 25.81 (3-CH3) , 32.21 (C9) , 34.29 (C7) , 36.77 (C4), 37.60 (C6), 43.59 (C8a), 51.59 (C5a), 73.14 (C10), 81.26 (C12a), 90.95 (C12), 102.38 (C3), 126.23, 126.38, 127.80 (C6H5 Cmeta, Cpara, Cortho) , 141.15 (C6H5 Cipso) . Mass spectrum: m/z 326 (M+-H2O, 0.4%), 312 (M-O2, 13), 298 (12), 254 (16) , 240 (23) , 182 (100) , 124 (68) , 118 (52) ,
105 (31) , 91 (32) , 55 (23) , 43 (46) , 28 (61) .
Example 11
d) Allyl Deoxoqinghaosu (12)
The allyl alcohol (5) (46 mg; 0.18 mmol) was submitted to the same conditions as described in a) . Allyl deoxoqinghaosu (12) was then obtained by flash chromatography (ether/light petroleum, 10:90) as a crystalline solid (18.3 mg; 36%) and as a 1:3 mixture of α- and ß-epimers with respect to the allyl group, H NMR spectrum (200 MHz, CDCl3) δ 0.782 [3H, d, JMe9=7.2 Hz, 9-CH3(α)], 0.888 [3H, d, JMe,9=7-6 Hz, 9-CH3(ß)], 0.951 [3H, d, JMe,6=6·0 Hz, 6-CH3(α)], 0.965 [3H, d, JMe,6=5.8 Hz, 6-CH3(ß)], 1.417 (3H, s, 3-CH3), 2.69 [1H,ddq, J98a=7.9, J9,Me=7.3, J9,10=6.3 Hz, H9(ß)], 3.491 [1H, ddd, J10,1,=10.2, J10,9=6.0, J10,1,=3.7 Hz, H10(α)], 4.304 [1H, ddd, J10,1,=10.0, J10,9=,6.1, J10,1,=4.3 Hz, H10(ß)], 5.02-5.18 (2H, m, H3'), 5.249 [1H, s, H12(α)], 5.332 [1H, s, H12(ß)], 5.73-6.17 (1H, m, H2'). 13C NMR spectrum (50 MHz, CDCI3) δ 12.99 [9-CH3(ß)], 13.60 [9-CH3(α)], 20.20 [6-CH3(ß)], 20.33 [6-CH3(α)], 21.51 (CH2), 24.72. (CH2), 24.90 (CH2), 26.09 (3-CH3), 30.21 [C9(ß)], 31.03 [C9(α)], 34.23 [C7(ß)], 34.49 [C7(α)], 36.35 [C4(α)], 36.61 [C4(ß)], 37.16 (CH2), 37.40 [C6(α)], 37.49 [C6(ß)], 44.33 [C8a(ß)], 46.07 [C8a(α)], 52.00 [C5a(α)], 52.36 [C5a(ß)], 73.87 [C10(α)], 74.73 [C10(ß)], 80.70 [C12a(α)], 81.08 [C12a(ß)l, 89.10 [C12(ß)3, 92.02 [C12(α)], 103.14
[C3(ß)], 103.97 [C3(α)], 116.08 [C3' (ß)], 116.42 [C3' (α)], 134.92 [C2' (α)3, 136.48 [C2' (ß)] .
Example 12
e) Carboxybutyl Deoxoqinghaosu (13a), (13b)
The hydroxy acid (7a) (30.2mg; 93.7 μmol) was submitted to the same conditions as described in a). The resulting crude product was then fractionated by chromatography on silicic acid (ether/light petroleum, 50:50) to give the ß-epimer of carboxybutyl deoxoqinghaosu (13a) as a colourless viscous oil (11.9 mg; 34%). 1H NMR spectrum (200 MHz, CDCI3) δ 0.857 (3H, d, J9-Me,9=7.6 Hz, 9-CH3), 0.961 (3H, d, J6-Me,6=5.8 Hz, 6-CH3), 1.419 (3H, s, 3-CH3), 4.150 (1H, ddd, J10,1,=10.1, J10,9=6.2, J10r=2.2 Hz, H10), 5.298 (1H, s, H12). 13C NMR spectrum (50 MHz, CDCI3) δ 13.01 (9-CH3), 20.19 (6-CH3), 24.63, 24.63, 24.86 (C1', C5, C8), 26.10 (3-CH3), 27.03, 29.01 (C3', C2'), 30.26 (C9), 33.88 (C4'), 34.45 (C7), 36.57 (C4), 37.44 (C6), 44.39 (C8a), 52.36 (C5a), 75.37 (C10), 81.13 (C12a), 88.99 (C12), 103.22 (C3), 178.98 (C5'). Similarly, the hydroxy acid (7b) (18.3 mg; 57 μmol) was converted into the α-epimer of carboxybutyl deoxoqinghaosu (13b) (8.4 mg; 40%). 1H NMR spectrum (200 MHz, CDCl3) d 0.777 (3H, d, J9-Me,9=7.4 Hz, 9-CH3), 0.953 (3H, d, J6-Me,6=6-2 Hz, 6-CH3), 1.409 (3H, s, 3-CH3), 3.42 (1H, m, H10), 5.219 (1H, s, H12). Example 13
f) Dimethyl Deoxoqinghaosu (14)
The dimethyl alcohol (8) (53 mg; 0.21 mmol) was submitted to the same conditions as described in a). Dimethyl deoxoqinghaosu (14) was then isolated by flash chromatography on silica (ether/light petroleum/ 20:80) as a viscous oil which slowly crystallised (22 mg; 35%). 1H NMR spectrum (200 MHz, CDCl3) δ 0.887 (3H, d, J9-Me,9 = 7.5 Hz, 9-CH3), 0.959 (3H, d, J9-Me,6 = 5'8 Hz, 6-CH3), 1.228 (3H, s, 10-CH3), 1.325 (3H, s, 10-CH3), 1.424 (3H, s, 3-CH3), 1.36-1.93 (9H, m), 2.027 (1H, ddd, J = 14.4, J = 4.7, J = 3.1 Hz), 2.277 (1H, ddd, J = 13.9, J - 13.4, J = 4.0 Hz), 2.433 (1H, dq, J99,-Me = 7·5' J9,8a = 4.3 Hz, H9), 5.313 (1H, s, H12). 13C NMR spectrum (50 MHz, CDCI3) δ 13.9.6 (9-CH3), 20.41 (6-CH3), 20.76 (10-CH3), 23.81 (C8), 24.56 (C5), 26.32 (3-CH3), 31.91 (C9), 34.76 (C7), 35.68 (10-CH3), 36.58 (C4), 37.48 (C6), 46.28 (C8a), 52.80 (C5a), 76.3 - 77.6 (C10, obscured by CDCl3), 80.97
(C12a), 88.94 (C12), 103.84 (C3). Mass spectrum: m/z 264 (M-O2, 7%), 250 (28), 235 (17), 207 (17), 206 (17), 192 (73), 177 (100), 165 (32), 138 (48), 123 (24), 109 (24), 95 (28), 81 (23), 69 (37), 55 (52), 43 (95), 28 (21). Preparation of Dehydroqinghaosu Adducts
Example 14
a) With thiophenol
A solution of dehydroqinghaosu (17.6 mg; 62.7 μmol) in chloroform (2 ml) was treated with thiophenol (6.5 μl; 62.7 μmol) and triethylamine (4 μl) with cooling in an ice bath. The whole was then stirred at room temperature under nitrogen for 24 h. Aqueous workup afforded the phenylthio derivative (15) as a 1:2 mixture of ß- and α- epimers in essentially quantitative yield and free of byproducts (23.9 mg; 98%). 1H NMR spectrum (600 MHz, CDCl3) δ 0.992 [3H, d, JMe,6=6.3 Hz, 6-CH3(α)], 1.007 [3H, d, JMe,6=5.9 Hz, 6-CH3(ß)], 1.419 [3H, s, 3-CH3(ß)], 1.451 [3H, s, 3-CH3(α)], 2.272 [1H, ddd, J91>=9.4, J9,1,=3.4, J9,8a=1 Hz, H9 (a)], 2.834 [1H, dd, Jgem=13.7, J1,,9=11.8 Hz,
H1'(ß)], 3.139 [1H, dd, Jgem=13.8, J1,,9=11.7 Hz, H1'(α)],
3.446 [1H, ddd, J9,1,=11.8, J9,1,=5, J9,8a=5 Hz, H9 (ß)], 3.776
[1H, dd, Jgem=13.8, J1,,9=4.4 Hz, H1'(ß)], 3.860 [1H, dd,
Jgem=13.8, J1,,9=3.4 Hz, H1' (α)], 5.864 [1H, s, H12(ß)], 5.918 [1H, s, H12(α)], 7.18-7.40 (5H, m, SPh).
Example 15
b) With thioglycolic acid.
A solution of dehydroqinghaosu (14.4 mg; 51.4 μmol) in chloroform (2 ml) was treated with thioglycolic acid (3.6 ftl; 51.4 μmol) and triethylamine (7.2 μl; 51.4 μmol). The whole was stirred at room temperature under nitrogen for 3 d before being quenched with NaHCO3 solution (0.3 M). The resulting mixture was extracted with ether and then the aqueous phase was acidified (HCl, 0.1M) to pH 6. Extraction of the aqueous phase with ether followed by the usual workup afforded the adduct (16) as a 2:1 mixture of ß- and α-epimers (15.4 mg; 81%). These were separated by chromatography on silicic acid (ether/light petroleum, 60:40) as very hygroscopic fine white solids. First was obtained the ß-epimer. 1H NMR spectrum (200
MHz, CDCl3) δ 1.007 (3H, d, J9-Me,6 = 5.6 Hz, 6-CH3), 1.447
(3H, s, 3-CH3), 5.878 (1H, s, H12). Next was obtained the α-epimer. 1H NMR spectrum (200 MHz, CDCl3) δ 1.004
(3H, d, J6-Me,6 = 5.6 Hz, 6-CH3), 1.449 (3H, S, 3-CH3), 5.956 (1H, s, H12).
Example 16
c) With methyl thioglycolate .
Dehydroqinghaosu (16.7 mg; 59.5 μmol) was treated with methyl thioglycolate (5.3 μl; 59.5 μmol) and triethylamine (4 μl) in chloroform (2 ml) for 3 d as described above. The reaction mixture was evaporated to dryness and then fractionated by flash chromatography (ether/light petroleum, 50:50) to give the ß-epimer as the least polar fraction (13.8 mg; 60%) and as very fine needles, 1H NMR spectrum (200 MHz, CDCl3) δ 1.00 (3H, d, JMe,6=5.9 Hz, 6-CH3), 1.44 (3H, s, 3-CH3), 2.65 (1H, dd, Jgem=13.2, J1,,9=10.6 HZ, H1'), 3.21 (1H, d, Jgem=14.9 Hz, H1"), 3.32 (1H, d, Jgem=14.9 Hz, H1"), 3.40 (1H, dd, Jgem=13.1, J1,,9=5.0 Hz, H1'), 3.51 (1H, ddd, J9,1,=10.8, J9,1,=5 . 0 , J9,8a=5 Hz , H9 ) , 3 . 757 (3H, s , OCH3) , 5 . 871 (1H, s, H12), and the α-epimer (6.4 mg; 28%) as a viscous oil, 1H NMR spectrum (200 MHz, CDCl3) δ 1.00 (3H, d, J9-Me,6 = 5.3 Hz, 6-CH3), 1.45 (3H, s, 3-CH3), 1.2 - 2.5 (11H, m), 2.39 (1H, ddd, J9,1, = 11.2, J9,1, = 4.0, J9,8a = 1.2 Hz, H9), 3.00 (1H, dd, Jgem = 13.3, J1,,9 = 11.3 Hz, H1'), 3.25 (1H, d, Jgem = 14.9 Hz, H1"), 3.32 (1H, d, Jgem = 14.9 Hz, H1"), 3.41 (1H, dd, Jgem = 13.2, J1,,9 = 3.9 Hz, H1'), 3.74 (3H, s, OCH3), 5.95 (1H, s, H12) .
Example 17
d) With mercaptopropionic acid
A solution of dehydroqinghaosu (24.9 mg; 89 μmol) in chloroform (2 ml) was treated with mercaptopropionic acid
(7.8 μl; 89 μmol) and triethylamine (12.4 μl; 89 μmol) with stirring at room temperature under nitrogen for 24 h and then for a further 24 h allowing the solvent to slowly evaporate away. The whole was diluted with ether and washed with dilute HCl solution. The ether solution was dried (MgSO4) and evaporated to dryness to give the crude adduct which was submitted to chromatography on silicic acid (ether/light petroleum, 75:25). The first compound to be eluted was the ß-epimer which was obtained as a fine white solid (8.2 mg; 24%). % NMR spectrum (600 MHz, CDCl3) δ 1.008 (3H, d, J6-Me,6 = 5.7 Hz, 6-CH3), 1.041 - 1.155 (2H, m), 1.40 - 1.51 (4H, m), 1.445 (3H, s, 3-CH3), 1.76 - 1.83 (2H, m), 2.141 (1H, ddd, J = 13.0, J
= 4.6, J = 4.6 Hz), 2.42 - 2.47 (1H, m), 2.554 (1H, dd,
Jgem =13.5, J1,,9 =11.9 Hz, H1'), 2.67 - 2.70 (2H, m, 2 X
H2"), 2.79 - 2.81 (2H, m, 2 X H1"), 3.334 (1H, dd, Jgem =
13.6, J1,,9= 4-6 Hz, H1'), 3.449 (1H, ddd, J9,1, = 11.6, J9,1, = 4.8, J9,8a = 4.8 Hz, H9) , 5.865 (1H, s, H12) . Next was obtained the α-epimer as a viscous oil (24.5 mg; 71%) . 1H NMR spectrum (200 MHz, CDCl3) δ 1.060 (3H, d, J6-Me,6 = 5'8 Hz' 6"CH3) , 1-506 (3H, s, 3-CH3) , 1.15 - 2.61 (11H, m, 2 X H4, 2 X H5, H5a, H6, 2 X H7, 2 X H8, H8a),
2.355 (1H, ddd, J9,1, = 11.5, J9,1, = 3.7, J9,8a = 1.0 Hz, H9), 2.70 - 2.90 (4H, m, 2 XH1", 2 X H2") , 2.952 (1H, dd, J1,,1, = 13.3, J1,,9 = 11.6 Hz, H1'), 3.401 (1H, dd, J1,,1, = 13.3, J1,,9 - 3.7 Hz, H1'), 5.96 (1H, s, H12) . Example 18
e) With methyl mercaptopropionate
Dehydroqinghaosu (29.4 mg; 0.105 mmol) in chloroform (3 ml) was treated with methyl mercaptopropionate (11.6 μl; 0.105 mmol) and triethylamine (4 μl) with stirring as described above. After 48 h the whole was evaporated to dryness and the residue was submitted to flash chromatography (ether/light petroleum, 50:50) to give first the ß-epimer as a fine white solid (18.3 mg; 44%). 1H NMR spectrum 200 MHz, CDCl3) δ 1.01 (3H, J6-Me,6 = 5.8 Hz, 6-CH3), 1.45 (3H, s, 3-CH3), 1.0- 1.9 (6H, m), 2.0 - 2.2 (3H, m), 2.4 - 2.5 (2H, m), 2.54 (1H, dd, Jgem = 13.2, Jr 9 = 11.4 Hz, H1'), 2.59 - 2.67 (2H, m, 2 X H2"), 2.76 - 2.84 (2H, m, 2 X H1"), 3.33 (1H, dd, Jgem = 13.3, J1,,9 = 4.7 Hz, H1'), 3.44 (1H, ddd, J9,1, = 11.5, J9,1, = 4.9, J9,8a = 4.9 Hz, H9), 3.71 (3H, s, OCH3), 5.67 (1H, s, H12).13C
NMR spectrum (50 MHz, CDCl3) δ 19.76 (6-CH3), 22.97 (C7),
24.84 (C8), 25.12 (3-CH3), 26.98 (CH2), 28.86 (CH2), 33.30
(CH2), 34.41 (CH2), 35.83 (CH2), 37.51 (C6), 37.55 (C8a), 41.17 (C5a), 49.97 (C9), 51.83 (OCH3), 79.24 (C12a), 93.80 (C12), 105.49 (C3), 170.17 (COOCH3), 172.08 (C10). Next was obtained the α-epimer as a viscous oil (9.7 mg; 23%). 1H NMR spectrum (200 MHz, CDCl3) δ 1.00 (3H, d, J6_ Me,6 = 5.7 Hz, 6-CH3), 1.1 - 1.6 (5H, m), 1.45 (3H, s, 3- CH3), 1.65 -1.83 (2H, m), 1.69 -2.08 (2H, m), 2.14 (1H, br dd, Jgem = 13.7, J = 4.5 Hz), 2.29 (1H, ddd, J9,1, = 11.6, J9,1, = 3.7, J9,8a = 1.1 Hz, H9), 2.3 - 2.47 (1H, m), 2.59 - 2.67 (2H, m, 2 X H2"), 2.76 - 2.84 (2H, m, 2 X H1"), 2.88 (1H, dd, Jgem = 13.2, J1,,9 = 11.6 Hz, H1'), 3.33 (1H, dd, Jgem = 13.2, J1,,9 = 3.7 Hz, H1'), 3.70 (3H, s, OCH3), 5.95 (1H, s, H12). When the solvent was changed to dichloromethane the ß-epimer was obtained in only 15% yield and the α-epimer in 77% yield. Example 19
f) With thioglycerol
Dehydroqinghaosu (14.6 mg; 52 μmol) in chloroform (2 ml) was treated with thioglycerol (5.6 mg; 4.3 μl; 52 μmol) and triethylamine (4 μl). The whole was stirred at room temperature overnight after which time complete reaction had taken place. The reaction mixture was evaporated to dryness to give the crude ß- and α-epimeric adducts in a ratio of 2.2 : 1. These were separated by flash chromatography on silica (ethyl acetate/light petroleum, 80 : 20) to give first, the ß-epimer as a mixture of diastereomers at C2" and as a fine white solid (12.2 mg; 60%). 1H NMR spectrum (400 MHz, CDCl3) (*denotes other diastereomer) δ 1.012 (3H, d, J6-Me6 = 5-7 Rz, 6-CH3), 1.07 - 1.14 (2H, m), 2.00 - 2.18 (3H, m), 2.40 - 2.48 (1H, m), 2.54 - 2.74 (3H, m) , 3.320 (1H, ddd, J = 13.1, J = 7.9, J = 4.8 Hz) , *3.473 (1H, ddd, J9,1, = 11.2, J9,1, = 5.9, J9,8a = 3.6 Hz, H9) , 3.482 (1H, ddd, J9,1, = 10.9, J9,1, = 5.4, J98a = 5.4 Hz, H9) , *3.572 (1H, dd, J = 11.2, J = 5.8 Hz), 3.580 (1H, dd, J = 11.2, J = 5.9 Hz), 3.758 (1H, br ddd, J = 11.3, J = 3.0, J = 3.0 Hz) , 3.82 -3.88 (1H, m), 5.878 (1H, s, H12) . 13C NMR spectrum (50 MHz, CDCI3) δ 19.79 (6-CH3), 23.17 (C8) , 24.85 (C5) , 25.14 (3-CH3), 28.92, 29.72 (CH2), 30.94 (C9), 33.35 (C7), 35.87 (C6), 37.53 (CH), 37.80, 38.19 (CH) 41.52, 41.73 (CH), 50.01
(C5a), 65.29 (C3"), 69.74, 70.37 (C2"), 79.29 (C12a),
93.89 (C12), 105.59 (C3), 170.25 (C10). The α-epimer was obtained as a viscous oil and as a mixture of diastereomers at C2" (5.1 mg; 25%). 1H NMR spectrum (400 MHz, CDCl3) δ 1.009 (3H, d, J6-Me,6 = 6-1 Hz, 6-CH3), 1-16 - 1.34 (2H, m), 1.39 - 1.52 (2H, m), 1.452 (3H, s, 3-CH3), 1.70 - 1.82 (2H, m), 1.92 - 2.16 (3H, m), 2.31 - 2.43 (2H, m), 2.59 - 2.75 (3H, m), 2.933 (1H, ddd, J = 14.0, J = 11.1, J = 3.1 Hz), 3.329 (1H, ddd, J = 13.2, J = 13.2, J = 4.0 Hz), 3.55 - 3.60 (1H, m), 3.766 (1H, br d, J = 11.4 Hz), 3.81 - 3.89 (1H, m), 5.954 (1H, s, H12).
Example 20
g) With L-cysteine
L-Cysteine (5.8 mg; 36.8 μmol) was added as a solid to a stirred solution of dehydroqinghaosu (10.3 mg; 36.8 μmol) in methanol (1.5 ml) under nitrogen. Complete conversion to the adduct occurred almost immediately. The reaction mixture was then evaporated to dryness whereupon the crude residue was triturated with ether and the resulting fine white powder was obtained by filtration. The adduct (17), so obtained, was found to be only sparingly soluble in methanol and insoluble in most other solvents. Therefore, an estimate of the epimer ratio could not be made. 1H NMR spectrum (200 MHz, CD3OD) δ 0.87 [3H, d, JMe,6=6.4 Hz, 6-CH3(ß)], 1.006 [3H, d, J6-Me=5.8 Hz, 6- CH3(α)], 1.390 [3H, s, 3-CH3(ß)], 1.396 [3H, s, 3-CH3(α)], 2.821 [1H, dd, J1,,1,=12.9, J1,,9 = 10.0 Hz, H1'(ß)], 2.951 [1H, dd, J2",2" = 14.6, J2",1" = 8.5 Hz, H2"(α)], 2.966 [1H, dd, J2",2" = 14.4, J2",1" = 8.5 Hz, H2"(ß)], 3.167 [1H, dd, J2",2"= 14.6, J2",1" =4.0 Hz, H2"(α)], 3.191 [1H, dd, J2",2" = 14.4, J2",1" =4.0 Hz, H2"(ß)], 3.490 [1H, ddd, J9,1, = 10.0, J9,1,=5.4, J9,8 = 5.4Hz, H9(ß)], 3.702 [1H, dd, J1",2" = 8.6, J1",2" = 4.0 Hz, H1"(ß)], 3.749 [1H, dd, J1",2" = 8.4, J1",2" = 3.7 Hz, H1"(α)], 6.026 [1H, s, H12(ß)], 6.127 [1H, s, H12(α)]
Example 21
h) With N-acetyl-L-cysteine
Triethylamine (7.9 μl; 57 μmol) was added to a stirred solution of dehydroqinghaosu (15.9 mg; 57 μmol) and a suspension of N-acetyl-L-cysteine (9.3 mg; 57 μmol) in chloroform (3 ml). Deprotonation of the cysteine caused it to go into solution. The reaction mixture was stirred under nitrogen for 24 h and then for a further 24 h allowing the solvent to evaporate away slowly. Water was added and then the whole was extracted once with ether. The aqueous layer was separated and then acidified with 1 M hydrochloric acid in the presence of ether and extracted three times with more ether. The combined extracts were dried (MgSO4) and evaporated to dryness to give the cysteine adducts as a 1:1 mixture of α- and ß- epimers and as a viscous oil (18.9 mg; 75%). 1H NMR spectrum (200 MHz, CDCI3) δ 1.00 (3H, d, J6-Me,6 = 5.4 Hz, 6-CH3), 1.44 (3H, S, 3-CH3), 2.10 (3H, S, acetyl), 4.82 (1H, br m, Wh/2 = 15.7 Hz, N-H), 5.875 [1H, S, H12(ß)], 5.961 [1H, s, H12(α)], 6.822 (1H, dd, J2",1" = 7.9, J2",1" = 7.9 Hz, H2"), 7.45 (1H, br s, Wh/2 = 28.6 Hz, COOH).
Preparation of Ring-Contracted Analogues of Qinghaosu Derivatives
Example 22
a) Oxidative degradation of dihydroqinghao aldehyde (2)
A mixture of dihydroqinghao aldehyde (2) (105 mg; 0.48 mmol), DABCO (26 mg), cupric acetate monohydrate (50 mg) and 2,2' -bipyridyl (50 mg) in DMF (7 ml) was stirred for 12 h at 70-75° and then the solvent was removed under vacuum. The resulting residue was submitted to flash chromatography (ether/light petroleum, 1:5) to afford the ketone (23) as a colourless viscous oil (77 mg; 78%) [α]D 18-44.4° (c, 2.03, CHCI3). 1H NMR spectrum (400 MHz, CDCl3) δ 0.94 (3H, d, J=6 Hz), 1.65 (3H, s), 2.20 (3H,s), 2.95 (1H, br S), 4.48 (1H, s).
Example 23
b) Reduction
The ketone (23) (98 mg; 0.47 mmol) in methanol (3 ml) was treated with NaBH4, portionwise, at 0° until a t.l.c. monitor showed that the reaction was complete. Water was added and the whole was thoroughly extracted with ether. The combined ether extracts were washed with brine and dried (Na2SO4) and evaporated to dryness. The residue was then submitted to flash chromatography (ether/light petroleum, 2:8) to give the alcohols, (24a) and (24b) as a colourless viscous oil (98 mg; 99%) and as a 1:4 mixture of epimers. These were separated by h.p.l.c.
(ethyl acetate/light petroleum, 8:92, Whatman partisil 10
M9, semi-preparative) to give, firstly, epimer (24b)
[α]D 18-10.3° (c, 2.34, CHCl3). 1H NMR spectum (400 MHz,
CDCl3) δ 0.88 (3H, d, J=6 Hz), 1.24 (3H, d, J=6 Hz), 1.63 (3H, br s), 2.72 (1H, br s), 3.81 (1H, dq), 5.34 (1H, s).
The next to be eluted was epimer (24a) [α]D 18-8.5° (c,
1.68, CHCl3). 1H NMR spectrum (400 MHz, CDCl3) δ 0.89
(3H, d, J=6 Hz), 1.26 (3H, d, J=6.4 Hz), 1.62 (3H, br s),
2.46 (1H, br s), 3.775 (1H, dq), 5.14 (1H, s). Example 24
c) Oxygenation to deoxoqinghaosu analogues (25a) and (25b)
The major alcohol epimer (24b) (55.8 mg; 0.27 mmol) in acetonitrile (2 ml) and dichloromethane (1 ml) was irradiated under oxygen at -30° for 4 h in the presence of Rose Bengal sensitiser. The resulting hydroperoxide solution was then diluted with dichloromethane (7 ml) and treated with Cu(OTf)2 ( 0.027 mmol, 0.1 M in acetonitrile) as described for the preparation of the deoxoqinghaosu derivatives. The crude product mixture obtained after work-up was submitted to flash chromatography (ether/light petroleum, 1:6) to give the five membered ring analogue (25b) as a colourless viscous oil (19.1 mg; 28%) [α]D 20+120.2° (c, 1.1, CHCl3). 1H NMR spectrum (400 MHz, CDCI3) δ 0.98 (3H, d, J=6 Hz), 1.45 (3H, s), 1.47 (3H, d, J=6.5 Hz), 3.93 (1H, dq), 5.59 (1H, s). Similarly, the minor alcohol epimer (24a) (20 mg; 96 μmol) was converted into the five membered analogue (25a) (7.8 mg; 32%). 1H NMR spectrum (400 MHz, CDCl3) δ 0.98
(3H, d, J=6 Hz), 1.24 (3H, d, J=6.4 Hz), 1.44 (3H, s), 4.92 (1H, dq), 5.67 (1H,s).
Activity data
The testing results for the qinghaosu derivatives are as follows:
Ethyl deoxoqinghaosu has been tested against two strains of Plasmodium falciparum concurrently with artemether and sodium artesunate, the latter two compounds being in clinical use at the present time. The results are shown in the following graphs.
Kl strain from Kanchanaburi, Thailand (chloroquine resistant)
IC50 = 6.0 nM = 2.0 ng/ml
FC27 strain from Madang, Papua New Guinea (chloroquine sensitive)
IC50 = 4.3 nM = 1.3 ng/ml
In vitro effects of ethyldeoxoqinghaosu, artemether and artesunate against the FC27 strain of Plasmodium falciparum
In vitro effects of ethyldeoxoqinghaosu, artemether and artesunate against the K1 strain of Plasmodium falciparum
Effect of qinghaosu analogues on Toxoplasma gondii in vitro*
OHS Analogue IC50 (μM)
9 Deoxoqinghaosu 0.28 qinghaosu (natural compound) 0.9 qinghaosu (prepared from qinghao acid) 0.85
Dehydroqinghaosu sample 1 1.7
Dehydroqinghaosu sample 2 1.7
17 ß-epimer 2.2
19 ß-epimer 2.4
19 α-epimer 4.4
18 ß-epimer 4.8
18 α-epimer 14
Pyrimethamine (known compound) 1 * [3H]-uracil incorporation assay

Claims (14)

Claims
1. Compounds of formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof
wherein
l = 1, 2 or 3
n is an integer from 1-6
where X is independently selected from
H, =O,=CH2, aryl, COR, OR, COOR or
X = -(CR1R2)r-R3 where r is an integer from 1-10 and where r > 1, optionally at least 1 carbon atom can be replaced by O, S or N;
R1, R2 and R3 are independently selected from
H; alkyl, alkenyl, alkynyl, aryl, each optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, aryl, halogen, OR, CF3, NO2, COOR, NRR', SR, COR, CONRR' , SO3R, SO2NRR' , SR, SOR, and SO2R, where R and R' are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted arylalkyl wherein the optional substituents are as defined above; provided that (C)1-(X)n is not -CH2-CH(CH3)-.
2. A process for preparing compounds of formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof comprising:
(A) carrying out at least one addition reaction on a compound of formula (II) having a -C=O functionality
to provide another compound of formula (II) with an alcoholic functionality at the (C)l-(V)r group and then followed by oxygenation to give a compound of formula (I);
where V is as defined for X; r and 1 are as defined above ;
(B) directly oxygenating a compound of formula (II) where there is a carboxylic functionality at the (C)l-(V)r reactive chain and also a further functional group to facilitate subsequent addition reaction, to provide compounds of formula (I) and then carrying out a suitable addition reaction to provide the required side chain; or
(C) for compounds of formula (I) where 1=1; carrying out one or more of the following steps on a compound of general formula (II):
(i) oxidative degradation and
(ii) reduction followed by oxygenation to give compounds of formula (I).
3. A process according to claim 2 wherein the oxygenation step in process A, B or C comprises (i) initial irradiation under oxygen in the presence of a catalyst such as Rose Bengal and
(ii) further oxygenation by treatment with a transition metal catalyst.
4. A process according to claim 3 wherein the transition metal catalyst is one or more selected from
Cu(OSO2CF3)2, copper(II) carboxylic salts and iron(III) salts.
5. A process according to claim 4 wherein the Cu(II) carboxylic salt is Cu(II) propionate or copper(II) 2-ethylhexanoate and the iron (III) salt is Fe(phenanthroline)3(PF6)3.
6. A process according to claim 5 wherein process step A comprises (i) treatment of the aldehyde 2 with A-MgBr, where A is alkyl, aryl or alkenyl to provide the respective derivatives;
followed by oxygenation to provide a compound of formula (I); (ii) treatment of
with MeMgI to provide
followed by oxygenation to provide a compound of formula (I); or
(iii) treatment of the aldehyde 2 with (EtO)2CH-A- MgBr where A is alkyl;
followed by hydrolysis and then oxidation to the HO(O=)C-A derivative;
followed by oxygenation to provide a compound of formula (I).
7. A process according to claim 5 wherein in process B the starting compound of formula (II) is dehydroqinghao acid which is oxygenated to provide dehydroqinghaosu and the addition reaction is carried out by treating dehydroqinghaosu with thiol nucleophiles.
8. A process according to claim 7 wherein the thiol nucleophile is thiophenol, thioglycolic acid, methyl thioglycolate, mercaptopropionic acid, methyl mercaptopropionate, thioglycerol, L-cysteine or N-acetyl-L-cysteine.
9. A process according to claim 5 wherein process (C) comprises
(i) oxidative degradation of aldehyde 2
(ii) reduction to the alcohol
(iii) followed by oxygenation to provide a compound of formula (I).
10. Compounds of general formula (II)
wherein V is as defined for X; r and l are as hereinbefore defined; provided that the (C)l-(V)r group is not CH(CH3)CH2OH and CH(CH3)C(=O)H.
11. A pharmaceutical composition comprising a compound of formula (I), a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof in a pharmaceutically acceptable carrier and/or diluent.
12. A method of treatment or prophylaxis of parasitic or viral diseases in a mammal comprising administering to the mammal a compound of formula (I), a pharmaceutically acceptable salt thereof or a stereoisomeric form thereof.
13. Use of a compound of formula (I), a pharmaceutically acceptable salt thereof or a stereoisomeric form thereof in the manufacture of a medicament for the treatment or prophylaxis of parasitic or viral diseases.
14. A compound of formula (I) substantially as herein described with reference to any one of examples 9-21 or 24.
AU27672/92A 1991-10-14 1992-10-14 Cyclic peroxyacetal compounds Ceased AU659505B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU27672/92A AU659505B2 (en) 1991-10-14 1992-10-14 Cyclic peroxyacetal compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPK887591 1991-10-14
AUPK8875 1991-10-14
PCT/AU1992/000548 WO1993008195A1 (en) 1991-10-14 1992-10-14 Cyclic peroxyacetal compounds
AU27672/92A AU659505B2 (en) 1991-10-14 1992-10-14 Cyclic peroxyacetal compounds

Publications (2)

Publication Number Publication Date
AU2767292A true AU2767292A (en) 1993-05-21
AU659505B2 AU659505B2 (en) 1995-05-18

Family

ID=3775744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27672/92A Ceased AU659505B2 (en) 1991-10-14 1992-10-14 Cyclic peroxyacetal compounds

Country Status (3)

Country Link
JP (1) JPH07500325A (en)
AU (1) AU659505B2 (en)
WO (1) WO1993008195A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156790A (en) * 1997-12-30 2000-12-05 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
US6160004A (en) * 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
IL140402A0 (en) * 1998-07-14 2002-02-10 Bayer Ag Antiparasitic artemisinin derivatives (endoperoxides)
WO2000004025A1 (en) * 1998-07-14 2000-01-27 The Hong Kong University Of Science & Technology Antiparasitic artemisinin derivatives (endoperoxides)
US6649647B1 (en) * 1998-07-14 2003-11-18 Richard Haynes Trioxane derivatives
US6297272B1 (en) 1999-01-12 2001-10-02 Hauser, Inc. Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same
JP3418724B2 (en) * 2000-02-10 2003-06-23 国立医薬品食品衛生研究所長 Sesquiterpenoid compounds and pharmaceuticals containing the same
KR100529600B1 (en) 2003-01-23 2005-11-22 정만길 Deoxoartemisinin analogs, process for their preparation, and anticancer agent comprising them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH679486A5 (en) * 1986-12-18 1992-02-28 Stanford Res Inst Int
US4916204A (en) * 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
CN1041595A (en) * 1988-10-04 1990-04-25 赫彻斯特股份公司 New artemisin derivative, its method for making and as the application of antiprotozoan agent,
AU640171B2 (en) * 1989-09-27 1993-08-19 Rhone-Poulenc Rorer S.A. Cyclic peroxyacetal lactone, lactol and ether compounds
TW198722B (en) * 1990-05-07 1993-01-21 Hoechst Ag

Also Published As

Publication number Publication date
JPH07500325A (en) 1995-01-12
AU659505B2 (en) 1995-05-18
WO1993008195A1 (en) 1993-04-29

Similar Documents

Publication Publication Date Title
KR920004488B1 (en) Method for preparing 1-hydro-xyvitamin d compounds
US5489697A (en) Method for the preparation of (+)-calanolide A and intermediates thereof
US20080287433A1 (en) derivatives of artemisinin, and their uses in the treatment of malaria
AU2767292A (en) Cyclic peroxyacetal compounds
WO2000042046A9 (en) Artemisinin analogs having antimalarial, antiproliferative, and antitumor activities and chemoselective methods of making the same
EP2880023A1 (en) Griseofulvin derivatives
CH680000A5 (en)
CA2253912C (en) Taxane derivatives, the preparation thereof and formulations containing them
EP1687312B1 (en) Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof
EP0196943B1 (en) 8-thiotetrahydroquinoleine derivatives and their salts
HU182048B (en) Process for preparing brendane derivatives and brendane analogues
FR2733498A1 (en) NOVEL CYCLOHEXANIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2772765A1 (en) Benzo pyrano acridinone derivatives having antitumor activity
EP1297835B1 (en) Benzo[b]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof
JPH0352465B2 (en)
JP4417256B2 (en) Single pot conversion from artemisinin to arteether
US4730059A (en) 6&#39;-thiomethylsubstituted spectinomycins
FR2826005A1 (en) Production of galanthamine compounds used for treating e.g. neurological disorders involves oxidizing alpha beta ethylenic ketone compound into spirodienone compound
ES2316555T3 (en) ADDITIONAL REACTIONS WITHOUT CATALYZE.
FR2795071A1 (en) NOVEL 7-OXO-2,3,7,14-TETRAHYDRO-1H-BENZO [B] PYRANO [3,2, H] ACRIDINE CARBOXYLATE DERIVATIVES, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0049144B1 (en) 5-fluoro uracil derivatives
Williams et al. A new and efficient cyclization reaction to construct the bicyclomycin ring system: synthesis of N, N'-dimethyl-4-desmethylenebicyclomycin
KR100440798B1 (en) Process for preparing non-acetal artemisinin derivative and 10-benzenesulfonyldihydroartemisinin
FR2649981A1 (en) DIHYDROPYRIMIDOTHIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
KR0131997B1 (en) Antimalarial artemisinin derivatives